OncoMatch

OncoMatch/Clinical Trials/NCT06719700

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

Is NCT06719700 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Chemotherapy and Immunotherapy for toripalimab.

Phase 2RecruitingSun Yat-sen UniversityNCT06719700Data as of May 2026

Treatment: Chemotherapy · Immunotherapy · Angio-immuno kinase inhibitor · Consolidation Therapy with Toripalimab and SurufatinibBased on the preclinical rationale for combining surufatinib with immunotherapy, and the clinical efficacy observed with surufatinib in extensive-stage small cell lung cancer (ES-SCLC), the investigators hypothesize that incorporating surufatinib into the ADRIATIC regimen could further enhance survival in LS-SCLC. To evaluate this approach, the investigators plan to conduct a single-arm Phase II study to explore the safety and efficacy of concurrent chemoradiotherapy combined with toripalimab and surufatinib in treating LS-SCLC.

Check if I qualify

Extracted eligibility criteria

Cancer type

Small Cell Lung Cancer

Disease stage

Required: Stage I, II, III

Performance status

WHO 0–1

Prior therapy

Cannot have received: anti-PD-1 therapy

Previous Anti-PD-1/PD-L1 Therapy: Prior use of any anti-PD-1 or anti-PD-L1 antibodies.

Lab requirements

Blood counts

Absolute neutrophil count ≥1.5 × 10⁹/L. Platelet count ≥100 × 10⁹/L. Hemoglobin ≥9.0 g/dL.

Kidney function

Calculated creatinine clearance ≥50 mL/min using the Cockcroft-Gault formula.

Liver function

Serum bilirubin ≤1.5 × ULN. AST and ALT ≤2.5 × ULN.

Cardiac function

QTc interval (corrected by Bazett's formula) ≤470 ms, calculated from three ECG measurements.

Pulmonary Function: FEV1 ≥800 mL. Absolute neutrophil count ≥1.5 × 10⁹/L. Platelet count ≥100 × 10⁹/L. Hemoglobin ≥9.0 g/dL. Renal Function: Calculated creatinine clearance ≥50 mL/min using the Cockcroft-Gault formula. Serum bilirubin ≤1.5 × upper limit of normal (ULN). AST and ALT ≤2.5 × ULN. QTc interval (corrected by Bazett's formula) >470 ms, calculated from three ECG measurements [excluded].

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify